Improvement of estradiol-17β-d-glucuronide-induced cholestasis by sodium tauroursodeoxycholate therapy in rats

Scandinavian Journal of Gastroenterology

Volumn 32, Issue 9, 1997, Pages 947-952

  Kinbara, S ^a   Ishizaki, K ^a   Sakakura, H ^a   Hirabayashi, N ^a   Kasai, H ^a   Araki, T ^a  

^a Pharmacological Research Laboratory   (Japan)

Author keywords

Bile acids; Bile flow; Cholestasis; Estradiol 17 D glucuronide; Rats; Tauroursodeoxycholate; Ursedeoxycholic acid

Indexed keywords

ESTRADIOL 17 GLUCURONIDE; ESTRIOL; GLYCOCHOLIC ACID; TAUROCHOLIC ACID; TAURODEOXYCHOLIC ACID; TAUROURSODEOXYCHOLIC ACID; URSODEOXYCHOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE ACID SYNTHESIS; BILE COMPOSITION; BILE FLOW; BILE SECRETION; BILIARY EXCRETION; CONTROLLED STUDY; ESTROGEN METABOLISM; FEMALE; INTRAHEPATIC CHOLESTASIS; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030881569     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365529709011207     Document Type: Article

References (22)

1. Heikel TA, Lathe GH. The effect of oral contraceptive steroids on bile secretion and bilirubin Tm in rats. Br J Pharmacol 1970;38:593-601.
2. Metreau JM, Dhumeaux D, Berthelot P. Oral contraceptives and the liver. Digestion 1972;7:318-35.
3. Bennion LJ, Ginsberg RL, Garnick MB, Bennett PH. Effects of oral contraceptives on the gallbladder bile of normal women. N Engl J Med 1976;294:189-92.
4. Adlercreutz H, Svanborg A, Anberg A. Recurrent jaundice in pregnancy. II. A study of the estrogens and their conjugation in late pregnancy. Am J Med 1967;42:341-7.
5. Holzbach RT, Sanders JH. Recurrent intrahepatic cholestasis of pregnancy: observations on pathogenesis. JAMA 1965;193:542-4.
6. Meyers M, Slikker W, Pascoe G, Vore M. Characterization of cholestasis induced by estradiol-17β-D-glucuronide in the rat. J Pharmacol Exp Ther 1980;214:87-93.
7. Meyers M, Slikker W, Vore M. Steroid D-ring glucuronides: characterization of a new class of cholestatic agents in the rat. J Pharmacol Exp Ther 1981;218:63-73.
8. Poupon R, Balkau B, Eschwege E, Poupon R, the UDCA-PBC study group. A multicenter controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991;324: 1548-54.
9. Leuschner U, Fischer H, Kurtz W, et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989;97:1268-74.
10. O'Brien CB, Senior JR, Arora-Mirchandani R, Batta AK, Salen G. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology 1991;14:838-47.
11. Cotting J, Lentze MJ, Reichen J. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic tibrosis and longstanding cholestasis. Gut 1990;31:918-21.
12. Nakagawa M, Colombo C, Setchell KDR. Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration. Hepatology 1990;12:322-34.
13. Ullrich D, Rating D, Schröter W, Hanefeld F, Bircher J. Treatment with ursodeoxycholic acid renders children with biliary atresia suitable for liver transplantation. Lancet 1987;2:1324.
14. Lindor KD, Burnes J. Ursodeoxycholic acid for the treatment of home parenteral nutrition-associated cholestasis. A case report. Gastroenterology 1991;101:250-3.
15. Balistreri WF, A-Kader HH, Heubi JE, Setchell KDR, Whitington P. Ursodeoxycholic acid (UDCA) decreases serum cholesterol levels, ameliorates symptoms, and improves biochemical parameters in pediatric patients with chronic intrahepatic cholestasis. In: Paumgartner G, Stiehl A, Gerok W, editors. Bile acids as therapeutic agents. Falk Symposium 58. London: Kluwer Academic Publishers; 1990. p. 323-33.
16. Jacquemin E, Dumont M, Mallet A, Erlinger S. Ursodeoxycholic acid improves ethinyl estradiol-induced cholestasis in the rats. Eur J Clin Invest 1993;23:794-802.
17. Kitani K, Ohta M, Kanai S. Tauroursodeoxycholate prevents biliary protein excretion induced by other bile salts in the rat. Am J Physiol 1985;248:G407-17.
18. Scholmerich J, Baumgartner U, Miyai K, Gerok W. Tauroursodeoxycholate prevents taurolithocholate-induced cholestasis and toxicity in rat liver. J Hepatol 1990;10:280-3.
19. Kinbara S, Ishizaki K, Takeuchi Y, Miyazawa N, Araki T. Protection against α-naphthylisothiocyanate-induced acute cholestasis in mice by a novel taurine conjugate of ursodeoxycholate (UR-906). Jpn J Pharmacol 1993;63:125-7.
20. Sakakura H, Suzuki M, Kimura N, Takeda H, Nagata S, Maeda M. Simultaneous determination of bile acids in rat bile and serum by high-performance liquid chromatography. J Chromatogr 1993;621:123-31.
21. Adinolfi LE, Utili R, Gaeta GB, Abernathy CO, Zimmerman HJ. Cholestasis induced by estradiol-17β-D-glucuronide: mechanisms and prevention by sodium taurocholate. Hepatology 1984; 4:30-7.
22. Bouchard G, Yousef IM, Tuchweber B. Influence of oral treatment with ursodeoxycholic and tauroursodeoxycholic acids on estrogen-induced cholestasis in rats: effects on bile formation and liver plasma membranes. Liver 1993;13:193-202.